The main objective of the Molecular Cytology Core Facility (MCCF) is to provide to users state-of-the-arttechnologies in a multi-user environment, for preparation of tissue samples, for detection, precise localizationand analysis of the expression of molecules with important cell functions during development and in cancer.The technologies include in situ localization of mRNA and proteins, cell proliferation, stem cell potential anddifferentiation, apoptosis and senescence, angiogenesis and hypoxia, histological evaluation and molecularin situ characterization of phenotypes of knock- out, transgenic mice and human tumors. In addition to thetraining and assistance provided to the researchers in the execution of these technologies, automatedexperiments for in situ molecular detection are carried at the MCCF. The optical microscopes [wide field,laser scanning (point scanning, spinning disc and multiphoton)] are efficiently used by researchers for imageacquisition, including live imaging. Experienced MCCF staff is instrumental in assisting users withstereological analysis, co-localization studies and 3D reconstructions.Specific services provided are: tissue processing and sample preparation; execution of methods for in situmolecular detection; application of a wide range of optical microscopy techniques in conjunction with imageacquisition and analysis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA008748-43
Application #
7671817
Study Section
Subcommittee G - Education (NCI)
Project Start
2008-07-31
Project End
2012-12-31
Budget Start
2008-07-31
Budget End
2008-12-31
Support Year
43
Fiscal Year
2008
Total Cost
$261,850
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Cottrell, T R; Thompson, E D; Forde, P M et al. (2018) Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol 29:1853-1860
Pereira, PatrĂ­cia M R; Sharma, Sai Kiran; Carter, Lukas M et al. (2018) Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy. Nat Commun 9:5137
Mano, Roy; Di Natale, Renzo; Sheinfeld, Joel (2018) Current controversies on the role of retroperitoneal lymphadenectomy for testicular cancer. Urol Oncol :
Zhu, Guo; Benayed, Ryma; Ho, Caleb et al. (2018) Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma. Mod Pathol :
Gollub, Marc J; Hotker, Andreas M; Woo, Kaitlin M et al. (2018) Quantitating whole lesion tumor biology in rectal cancer MRI: taking a lesson from FDG-PET tumor metrics. Abdom Radiol (NY) 43:1575-1582
Rapp, Moritz; Wiedemann, Gabriela M; Sun, Joseph C (2018) Memory responses of innate lymphocytes and parallels with T cells. Semin Immunopathol 40:343-355
Rutter, Carolyn M; Kim, Jane J; Meester, Reinier G S et al. (2018) Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. Cancer Epidemiol Biomarkers Prev 27:158-164
Zabor, Emily C; Furberg, Helena; Lee, Byron et al. (2018) Long-Term Renal Function Recovery following Radical Nephrectomy for Kidney Cancer: Results from a Multicenter Confirmatory Study. J Urol 199:921-926
Bakhoum, Samuel F; Ngo, Bryan; Laughney, Ashley M et al. (2018) Chromosomal instability drives metastasis through a cytosolic DNA response. Nature 553:467-472
Pilewskie, Melissa; Morrow, Monica (2018) Margins in breast cancer: How much is enough? Cancer 124:1335-1341

Showing the most recent 10 out of 8799 publications